|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 601 13th St., NW |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20005-2000 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 46676-12
|
||||||||
|
6. House ID# 395790000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: AMY E. MODLIN |
Date | 10/20/2026 2:38:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues:
ACA Healthcare tax credits; Transparency in coverage; Surprise Billing; 2025 Proposed NBPP/Individual Market/ACA exchanges; Prior Authorization; Hospital Consolidation; Employer-provided health coverage; Cyber Attack/ Cyber Security; Community Health + Maternal Health; Hospital Billing; Anti-tiering, Anti-steering; Artificial Intelligence; Individual Market Reforms and eAPTC Extension; Healthcare Affordability
Bills:
H.R.4710 - No Surprises Act Enforcement Act
To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to increase penalties for group health plans and health insurance issuers for practices that violate balance billing requirements, and for other purposes.
Sponsor: Rep. Murphy, Gregory F. [R-NC-3]
S.2420 - No Surprises Act Enforcement Act
To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to increase penalties for group health plans, health insurance issuers, and nonparticipating providers or facilities for practices that violate balance billing requirements, and for other purposes.
Sponsor: Sen. Marshall, Roger [R-KS]
S.2355 - Patients Deserve Price Tags Act
To amend the Public Health Service Act to provide for hospital and insurer price transparency.
Sponsor: Sen. Marshall, Roger [R-KS]
H.R.8684 - Transparency in Billing Act of 2026
To amend the Employee Retirement Income Security Act of 1974 to require group health plans and health insurance issuers offering group health insurance coverage to only pay claims submitted by hospitals that have in place policies and procedures to ensure accurate billing practices, and for other purposes.
Sponsor: Rep. Foxx, Virginia [R-NC-5]
H.R.9393 - Lower Costs, More Transparency Act of 2026
To promote price transparency in the health care sector.
Sponsor: Rep. Guthrie, Brett [R-KY-2]
H.R.9397 - Premium Transparency Act
To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to ensure health insurer accountability through publishing of overhead costs and claim payments, and to direct the Secretary of Health and Human Services to issue guidance on the provision of certain insurance information.
Sponsor: Rep. Pfluger, August [R-TX-11]
H.R.9396 - Prior Authorization Accountability Act
To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to require the displaying of claim denial rates.
Sponsor: Rep. Goldman, Craig A. [R-TX-12]
H.R. 8209 - School Based-Health Centers Reauthorization Act
To amend the Public Health Service Act to reauthorize the school-based health centers grant program.
Sponsor: Rep. Tonko, Paul [D-NY-20]
H.R.9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026
To amend the Public Health Service Act to authorize funding for nutrition education and chronic disease prevention at federally qualified health centers, and for other purposes.
Sponsor: Rep. Harshbarger, Diana [R-TN-1]
H.R. 8201 - Expanding Community Access to Health Services Act
To amend Public Health Service Act to require community health centers to provide behavioral and mental health and substance use disorder services, and for other purposes.
Sponsor: Rep. Lee, Susie [D-NV-3]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Modlin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues:
Medicare Advantage & MA Rate Notice; Medicare/Transparency; Mental Health Care, Youth Mental Health; Site neutral payment reform; Program Fraud, Waste, and Abuse
Bills:
H.R.4077 - GUARD Veterans Health Care Act
To amend title 38, United States Code, and the Social Security Act to permit recovery from the Department of Veterans Affairs of costs from Medicare Advantage and Medicare prescription drug plans and to modify the authority for recovery by the United States of reasonable charges for certain care or services furnished to veterans for non-service-connected disabilities, and for other purposes.
Sponsor: Rep. Doggett, Lloyd [D-TX-37]
S.2145 - GUARD Veterans Health Care Act
To amend title 38, United States Code, and the Social Security Act to permit recovery from the Department of Veterans Affairs of costs from Medicare Advantage and Medicare prescription drug plans and to modify the authority for recovery by the United States of reasonable charges for certain care or services furnished to veterans for non-service-connected disabilities, and for other purposes.
Sponsor: Sen. Warren, Elizabeth [D-MA]
H.R.9392 - Medicare Advantage Cost Transparency Act
To amend title XVIII of the Social Security Act to require the inclusion of certain information in Medicare Advantage encounter data.
Sponsor: Rep. DeGette, Diana [D-CO-1]
H.R. 5243 - Supplemental Benefits Transparency Bill
To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage.
Sponsor: Rep. McClellan, Jennifer L. [D-VA-4]
H.R.3514 - Improving Seniors Timely Access to Care Act of 2025
To amend title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Sponsor: Rep. Kelly, Mike [R-PA-16]
H.R.8883 - Protecting Seniors and Stopping Fraudsters Act
To amend title XVIII of the Social Security Act to provide for additional oversight of hospice programs and home health agencies under the Medicare program, and for other purposes.
Sponsor: Rep. Van Duyne, Beth [R-TX-24]
H.R.8871 - DME Scammer Prevention Act of 2026
To amend title XVIII of the Social Security Act to promote Medicare program integrity with respect to certain medical equipment and supplies.
Sponsor: Rep. Bean, Aaron [R-FL-4]
H.R.9693 - Patients First Act of 2026
To amend title XVIII of the Social Security Act to modify certain physician payments under the Medicare program.
Sponsor: Rep. Joyce, John [R-PA-13]
H.R.8375 - Medicare Advantage Improvement Act of 2026
To amend title XVIII of the Social Security Act to provide for certain reforms under the Medicare Advantage program, and for other purposes.
Sponsor: Rep. Joyce, John [R-PA-13]
S.4384 - Medicare Advantage Improvement Act of 2026
To amend title XVIII of the Social Security Act to provide for certain reforms under the Medicare Advantage program, and for other purposes.
Sponsor: Sen. Marshall, Roger [R-KS]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Modlin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues:
Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy
Bills:
S.3014 - Ensuring Timely Access to Generics Act of 2025
To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S.1096 - Preserve Access to Affordable Generics and Biosimilars Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen. Klobuchar, Amy [D-MN]
S.1095 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen. Klobuchar, Amy [D-MN]
S.1302 - Increasing Transparency in Generic Drug Applications Act
To provide for increased transparency in generic drug applications.
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
H.R.1843 - Increasing Transparency in Generic Drug Applications Act
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Modlin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |